
Geographic Atrophy (GA)- Pipeline Insight, 2025
Description
DelveInsight’s, “Geographic Atrophy - Pipeline Insight, 2025, report provides comprehensive insights about 23+ companies and 25+ pipeline drugs in Geographic Atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Geographic Atrophy: Overview
Geographic atrophy (GA) is a chronic progressive degeneration of the macula, as part of late-stage age-related macular degeneration (AMD). The disease is characterized by localized sharply demarcated atrophy of outer retinal tissue, retinal pigment epithelium and choriocapillaris. It starts typically in the perifoveal region and expands to involve the fovea with time, leading to central scotomas and permanent loss of visual acuity. It is bilateral in most cases. Over 8 million people are affected worldwide with GA, approximately 20% of all individuals with AMD. The incidence of GA is expected to rise as the age-burden of developed countries is increasing. Several risk factors have been noted by several studies. The most pronounced risk factor is increasing age and family history of AMD. Smoking history increases the risk of GA significantly. Both active smokers, but also former smokers are at greater risk of developing geographic atrophy.
""""Geographic Atrophy - Pipeline Insight, 2025"""" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Geographic Atrophy pipeline landscape is provided which includes the disease overview and Geographic Atrophy treatment guidelines. The assessment part of the report embraces, in depth Geographic Atrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Geographic Atrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Geographic Atrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Geographic Atrophy Emerging Drugs
Further product details are provided in the report……..
Geographic Atrophy: Therapeutic Assessment
This segment of the report provides insights about the different Geographic Atrophy drugs segregated based on following parameters that define the scope of the report, such as:
Geographic Atrophy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Geographic Atrophy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Geographic Atrophy drugs.
Geographic Atrophy Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Geographic Atrophy: Overview
Geographic atrophy (GA) is a chronic progressive degeneration of the macula, as part of late-stage age-related macular degeneration (AMD). The disease is characterized by localized sharply demarcated atrophy of outer retinal tissue, retinal pigment epithelium and choriocapillaris. It starts typically in the perifoveal region and expands to involve the fovea with time, leading to central scotomas and permanent loss of visual acuity. It is bilateral in most cases. Over 8 million people are affected worldwide with GA, approximately 20% of all individuals with AMD. The incidence of GA is expected to rise as the age-burden of developed countries is increasing. Several risk factors have been noted by several studies. The most pronounced risk factor is increasing age and family history of AMD. Smoking history increases the risk of GA significantly. Both active smokers, but also former smokers are at greater risk of developing geographic atrophy.
""""Geographic Atrophy - Pipeline Insight, 2025"""" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Geographic Atrophy pipeline landscape is provided which includes the disease overview and Geographic Atrophy treatment guidelines. The assessment part of the report embraces, in depth Geographic Atrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Geographic Atrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Geographic Atrophy R&D. The therapies under development are focused on novel approaches to treat/improve Geographic Atrophy.
This segment of the Geographic Atrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Geographic Atrophy Emerging Drugs
- IONIS-FB-LRx: Ionis Pharmaceuticals
- Zimura: IVERIC bio
Further product details are provided in the report……..
Geographic Atrophy: Therapeutic Assessment
This segment of the report provides insights about the different Geographic Atrophy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Geographic Atrophy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Geographic Atrophy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Geographic Atrophy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Geographic Atrophy drugs.
Geographic Atrophy Report Insights
- Geographic Atrophy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Geographic Atrophy drugs?
- How many Geographic Atrophy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Geographic Atrophy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Geographic Atrophy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Geographic Atrophy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Ionis Pharmaceuticals
- IVERIC bio
- Apellis Pharmaceuticals, Inc.
- NGM Biopharmaceuticals
- Annexon Inc.
- Genentech
- Alexion AstraZeneca Rare Disease
- ONL Therapeutics
- Alkeus Pharmaceuticals
- Regenerative Patch Technologies, LLC
- Astellas Pharma Inc
- Gemini Therapeutics
- Boehringer Ingelheim
- Cell Cure Neurosciences LTD
- Stealth BioTherapeutics Inc.
- Hemera Biosciences LLC
- Gyroscope Therapeutics Limited
- Eyevensys
- Nanoscope Therapeutics, Inc.
- Catalyst Biosciences
- Novartis
- IONIS-FB-LRx
- Zimura
- APL-2
- MCO-020
- CB 2782
- NGM621
- HMR59
- GT 005
- Elamipretide
- ANX007
- RG6312
- OpRegen
- RG6147
- BI 754132
- ALXN2040
- ONL 1204
- ALK-001
- GEM103
- ASP7317
- CPCB-RPE1
Table of Contents
90 Pages
- Introduction
- Executive Summary
- Geographic Atrophy: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Geographic Atrophy – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Zimura: IVERIC bio
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- IONIS-FB-LRx: Ionis Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Geographic Atrophy Key Companies
- Geographic Atrophy Key Products
- Geographic Atrophy- Unmet Needs
- Geographic Atrophy- Market Drivers and Barriers
- Geographic Atrophy- Future Perspectives and Conclusion
- Geographic Atrophy Analyst Views
- Geographic Atrophy Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.